Explore
← New search
3 matching publication(s)
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).
PMID 38897205 · Cell Rep Med · 2024
L1
72/100
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells.
PMID 37081150 · Nat Immunol · 2023
L1
37/100
In vivo induction of activin A-producing alveolar macrophages supports the progression of lung cell carcinoma.
PMID 36650150 · Nat Commun · 2023
L1
96/100